Intelligence Report · ~14 min read
Cardiology · PAH Competitive Landscape
2 findings · 103 signals · 12 insights
Type
Competitive Landscape ReportGenerated
Jul 23, 2026
Confidence
High Confidence · 89%
Evidence
105 items
Sources
2
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Competitive landscape assessment for Cardiology · PAH synthesizes 2 Competitiva findings across 103 active signals. 0 high-pressure competitive threats identified. 8 companies maintain material exposure in this therapeutic area.
Key Developments
Material intelligence events ranked by strategic relevance.
- competitive
Lilly — Pipeline activity
Lilly is a direct competitive threat because it has a development-stage program in Cardiology · LDL-C lowering (Pipeline activity) and could narrow Novartis's development lead.
View detail - competitive
Merck — Pipeline activity
Merck is a direct competitive threat because it has a development-stage program in Cardiology · LDL-C lowering (Pipeline activity) and could narrow Novartis's development lead.
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Monitor 0 high-pressure competitive programs for portfolio displacement risk. Cross-reference 12 executive insights for synthesized strategic assessment. Leading competitive pressure: Medium across top-linked programs.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
Lilly — Pipeline activity
95%Lilly is a direct competitive threat because it has a development-stage program in Cardiology · LDL-C lowering (Pipeline activity) and could narrow Novartis's development lead.
Source: Lilly
View evidenceMerck — Pipeline activity
83%Merck is a direct competitive threat because it has a development-stage program in Cardiology · LDL-C lowering (Pipeline activity) and could narrow Novartis's development lead.
Source: Merck
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Approves First Oral PCSK9 Inhibitor Lipfendra for High Cholesterol
Regulatory Approval
- Merck's LIPFENDRA Approved as First Oral PCSK9 Inhibitor for Hypercholesterolemia
Regulatory Approval
- Medtronic Recalls Harmony Delivery Catheter Due to Detachment Risk
Safety Signal
- AstraZeneca's Dapagliflozin Approved for Heart Failure; Real-World Study Launched in Germany
Regulatory Approval
- FDA Approves Supplemental Application for BRILINTA (Ticagrelor)
Regulatory Approval
- AstraZeneca's Wainua fails primary endpoint in ATTR-CM Phase III trial
Trial Update
- SINGLE-AF Trial Evaluates DOACs in Intermediate Stroke Risk Atrial Fibrillation Patients
Trial Update
- Abiomed Recalls Impella CP Sets Due to Low Purge Pressure Risk
Safety Signal
Insights
- Strategic Implications of Lipfendra's Approval as First Oral PCSK9 Inhibitor
Cardiology · Cholesterol Management
- Merck's LIPFENDRA Approval Reshapes Hypercholesterolemia Treatment Landscape
Cardiology · Hypercholesterolemia
- AstraZeneca's Dapagliflozin Approval Enhances Competitive Position in Heart Failure Market
Cardiology · Heart Failure
- Mobile Technology's Potential to Transform Cardiac Rehabilitation Post-ACS
Cardiology · Rehabilitation
- Sanofi's Venglustat Trial: A Potential Game Changer in Fabry Disease Treatment
Cardiology · Fabry Disease
- Teva's Macitentan Approval Signals Increased Competition in Pulmonary Arterial Hypertension
Cardiology · Pulmonary Arterial Hypertension
- Eko Devices' Study on Electronic Stethoscope Could Disrupt Pulmonary Hypertension Diagnostics
Cardiology · Pulmonary Hypertension
- Cost-Effectiveness Analysis of Mavacamten: Strategic Implications for Market Access
Cardiology · Hypertrophic Cardiomyopathy
Companies
- Merck
132 signals
- AstraZeneca
127 signals
- Novartis
38 signals
- GSK
16 signals
- Teva
25 signals
- Bayer
13 signals
- Sanofi
11 signals
- Novo Nordisk
9 signals